I agree with you on that. If anything, it gives Kishbauch and company more incentive to sell out. But, it doesn't guarantee that another party will be interested in acquiring ACHN at all or at least at a fair price.
In listening to the past few CCs, I still get the impression that ACHN is likely not going to do anything until after the 3-month data is out on ACH-1625 at the end of the year. In one of the last calls they did indicate that they weren't ruling anything out but I still got the sense they will be waiting until the end of the year. They also noted for the first time that they have been in some discussions regarding clinical trial collaborations involving 1625 (similar to the BMY and VRUS collaboration). However, I think if they ultimately agree to this type of arrangement for 1625, this could have a detrimental effect on ACHN's share price. I think investors want to see ACHN land a nice partnership where they get a big up-front commitment and not just enter into a deal where they get absolutely nothing and the other party just agrees to test 1625 with their own compound. Of course, a buyout offer at the right price would be even better.
Market Data 
Markets 
AI
